Comparative Pharmacology
Head-to-head clinical analysis: VALPROATE SODIUM versus XCOPRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VALPROATE SODIUM versus XCOPRI.
VALPROATE SODIUM vs XCOPRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA levels by inhibiting GABA transaminase and blocking voltage-gated sodium channels; also modulates T-type calcium channels.
XCOPRI (cenobamate) is a tetrazole derivative anticonvulsant that reduces neuronal excitability through inhibition of voltage-gated sodium channels (persistent sodium current) and positive allosteric modulation of GABA-A receptors.
10-15 mg/kg/day orally or intravenously in 2-3 divided doses; increase by 5-10 mg/kg/day weekly to therapeutic range of 50-100 mcg/mL. Maximum dose 60 mg/kg/day.
Oral, 100 mg once daily for 2 weeks, then increase to 200 mg once daily. Maximum dose 400 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 9–16 hours in adults; may be shorter in children (5–12 hours) and prolonged in hepatic impairment or elderly (up to 18 hours). Neonatal half-life: 10–67 hours. Clinically, twice-daily dosing is typical.
50-70 hours, allowing once-daily dosing. Steady-state is reached in approximately 2 weeks.
Primarily renal (90% as glucuronide conjugates, 3-oxo derivative, and other metabolites; <3% unchanged). Biliary/fecal excretion accounts for <10%.
Primarily renal, with approximately 70% of the dose excreted as unchanged drug in urine and 30% as inactive metabolites. Fecal elimination accounts for <2%.
Category C
Category C
Anticonvulsant
Anticonvulsant